Gene Therapies Will Be A Bigger Cost Issue In 2021, PwC Predicts

 
• By Jessica Merrill

The expected launch of BioMarin's Roctavian for hemophilia A is expected to heighten the profile of expensive gene therapies on payers' radar. Specialty drug costs are expected to continue to grow in 2021. 

Money6
A new PwC report looks at medical cost trend in 2021 • Source: Shutterstock

More from Gene Therapies

More from Advanced Therapies